Browse Studies — Arctuva

Phase 1

A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tu…

Advanced LymphomaAdvanced Malignant Solid NeoplasmIndolent Non-Hodgkin Lymphoma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06223542

Phase 2

Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where i…

Advanced Anal CarcinomaAdvanced Biliary Tract CarcinomaAdvanced Bladder Carcinoma+41 more

Phase 1

Clinical Study Protocol AN4005X0101 An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients With Advanced Tumors

Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-hum…

Advanced Solid TumorAdvanced Lymphoma

Estimated

~$10 – $8,750

Adlai Nortye Biopharma Co., Ltd.NCT04999384

Phase 1

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with…

Advanced Solid TumorAdvanced Lymphoma

Estimated

~$10 – $8,750

CStone PharmaceuticalsNCT05279300